Vitamin D: the discovery of its metabolites and their therapeutic applications

Our understanding of the role of vitamin D in calcium-phosphorus metabolism has changed considerably in the last decade. Studies performed in tissue culture, animal, and man have firmly established that the natural compound requires hydroxylation in the liver at the C-25 position and in the kidney a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatrics (Evanston) 1976-05, Vol.57 (5), p.729-741
Hauptverfasser: Beale, M G, Chan, J C, Oldham, S B, Deluca, H F
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 741
container_issue 5
container_start_page 729
container_title Pediatrics (Evanston)
container_volume 57
creator Beale, M G
Chan, J C
Oldham, S B
Deluca, H F
description Our understanding of the role of vitamin D in calcium-phosphorus metabolism has changed considerably in the last decade. Studies performed in tissue culture, animal, and man have firmly established that the natural compound requires hydroxylation in the liver at the C-25 position and in the kidney at the C-1 position to form the biologically active derivative 1,25-(OH)2D3. These hydroxylation reactions are finely regulated to maintain normal calcium-phosphorus homeostasis: We now regard 1,25-(OH)2D3 as a hormone which is released by the kidney during periods of hypocalcemia. This hormone acts on the intestinal mucosa to facilitate calcium absorption and on bone to increase calcium mobilization. Its function in other tissues is still being evaluated. The active metabolites of vitamin D and several closely related analogs have been synthesized. It has been clearly demonstrated that 1,25-(OH)2D3 and 1alpha-OH-D3 promote healing in uremic bone disease. Administration of small amounts of these compounds has corrected the biochemical disturbances in vitamin D-dependency and hypoparathyroidism. Limited clinical experience with 25-OH-D3 and 1,25-(OH)2D3 in children with familial hypophosphatemia has failed to show convincing evidence of a therapeutic effect. Further clinical studies are needed to fully evaluate the therapeutic potential of this new family of compounds.
doi_str_mv 10.1542/peds.57.5.729
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_83443481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>83443481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c287t-d7d1a2e73a7d918bf2cf7d82dc2b142b7c4c5ddc1822e583dfaed66745788e853</originalsourceid><addsrcrecordid>eNpFkDtPwzAYRS3EqxRGNgZPbAm2Y9cuGypPqYIFWC3H_iKM8sJ2KvXfk9BKLPcuR1dXB6FLSnIqOLvpwcVcyFzkki0P0IySpco4k-IQzQgpaMYJEafoLMZvQggXkp2gY6qoZGKGXj99Mo1v8f0tTl-AnY-220DY4q7CPkXcQDJlV_sEEZvWTZAPUwbTw5C8xabva29N8l0bz9FRZeoIF_ueo4_Hh_fVc7Z-e3pZ3a0zy5RMmZOOGgayMNItqSorZivpFHOWlZSzUlpuhXOWKsZAqMJVBtxiIcfzSoESxRxd73b70P0MEJNuxuNQ16aFbohaFZwXXNERzHagDV2MASrdB9-YsNWU6EmfnvRpIbXQo76Rv9oPD2UD7p_-81X8ApimbLI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>83443481</pqid></control><display><type>article</type><title>Vitamin D: the discovery of its metabolites and their therapeutic applications</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Beale, M G ; Chan, J C ; Oldham, S B ; Deluca, H F</creator><creatorcontrib>Beale, M G ; Chan, J C ; Oldham, S B ; Deluca, H F</creatorcontrib><description>Our understanding of the role of vitamin D in calcium-phosphorus metabolism has changed considerably in the last decade. Studies performed in tissue culture, animal, and man have firmly established that the natural compound requires hydroxylation in the liver at the C-25 position and in the kidney at the C-1 position to form the biologically active derivative 1,25-(OH)2D3. These hydroxylation reactions are finely regulated to maintain normal calcium-phosphorus homeostasis: We now regard 1,25-(OH)2D3 as a hormone which is released by the kidney during periods of hypocalcemia. This hormone acts on the intestinal mucosa to facilitate calcium absorption and on bone to increase calcium mobilization. Its function in other tissues is still being evaluated. The active metabolites of vitamin D and several closely related analogs have been synthesized. It has been clearly demonstrated that 1,25-(OH)2D3 and 1alpha-OH-D3 promote healing in uremic bone disease. Administration of small amounts of these compounds has corrected the biochemical disturbances in vitamin D-dependency and hypoparathyroidism. Limited clinical experience with 25-OH-D3 and 1,25-(OH)2D3 in children with familial hypophosphatemia has failed to show convincing evidence of a therapeutic effect. Further clinical studies are needed to fully evaluate the therapeutic potential of this new family of compounds.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.57.5.729</identifier><identifier>PMID: 181725</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Calcium - metabolism ; Chemical Phenomena ; Chemistry ; Chronic Kidney Disease-Mineral and Bone Disorder - drug therapy ; Chronic Kidney Disease-Mineral and Bone Disorder - metabolism ; Dihydroxycholecalciferols - metabolism ; Epilepsy - drug therapy ; Humans ; Hydroxycholecalciferols - metabolism ; Hypoparathyroidism - metabolism ; Hypophosphatemia, Familial - metabolism ; Parathyroid Hormone - metabolism ; Phosphorus - metabolism ; Pseudohypoparathyroidism - metabolism ; Rickets - metabolism ; Space life sciences ; Structure-Activity Relationship ; Uremia - drug therapy ; Vitamin D - metabolism ; Vitamin D - therapeutic use ; Vitamin D Deficiency - metabolism</subject><ispartof>Pediatrics (Evanston), 1976-05, Vol.57 (5), p.729-741</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c287t-d7d1a2e73a7d918bf2cf7d82dc2b142b7c4c5ddc1822e583dfaed66745788e853</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/181725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Beale, M G</creatorcontrib><creatorcontrib>Chan, J C</creatorcontrib><creatorcontrib>Oldham, S B</creatorcontrib><creatorcontrib>Deluca, H F</creatorcontrib><title>Vitamin D: the discovery of its metabolites and their therapeutic applications</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>Our understanding of the role of vitamin D in calcium-phosphorus metabolism has changed considerably in the last decade. Studies performed in tissue culture, animal, and man have firmly established that the natural compound requires hydroxylation in the liver at the C-25 position and in the kidney at the C-1 position to form the biologically active derivative 1,25-(OH)2D3. These hydroxylation reactions are finely regulated to maintain normal calcium-phosphorus homeostasis: We now regard 1,25-(OH)2D3 as a hormone which is released by the kidney during periods of hypocalcemia. This hormone acts on the intestinal mucosa to facilitate calcium absorption and on bone to increase calcium mobilization. Its function in other tissues is still being evaluated. The active metabolites of vitamin D and several closely related analogs have been synthesized. It has been clearly demonstrated that 1,25-(OH)2D3 and 1alpha-OH-D3 promote healing in uremic bone disease. Administration of small amounts of these compounds has corrected the biochemical disturbances in vitamin D-dependency and hypoparathyroidism. Limited clinical experience with 25-OH-D3 and 1,25-(OH)2D3 in children with familial hypophosphatemia has failed to show convincing evidence of a therapeutic effect. Further clinical studies are needed to fully evaluate the therapeutic potential of this new family of compounds.</description><subject>Animals</subject><subject>Calcium - metabolism</subject><subject>Chemical Phenomena</subject><subject>Chemistry</subject><subject>Chronic Kidney Disease-Mineral and Bone Disorder - drug therapy</subject><subject>Chronic Kidney Disease-Mineral and Bone Disorder - metabolism</subject><subject>Dihydroxycholecalciferols - metabolism</subject><subject>Epilepsy - drug therapy</subject><subject>Humans</subject><subject>Hydroxycholecalciferols - metabolism</subject><subject>Hypoparathyroidism - metabolism</subject><subject>Hypophosphatemia, Familial - metabolism</subject><subject>Parathyroid Hormone - metabolism</subject><subject>Phosphorus - metabolism</subject><subject>Pseudohypoparathyroidism - metabolism</subject><subject>Rickets - metabolism</subject><subject>Space life sciences</subject><subject>Structure-Activity Relationship</subject><subject>Uremia - drug therapy</subject><subject>Vitamin D - metabolism</subject><subject>Vitamin D - therapeutic use</subject><subject>Vitamin D Deficiency - metabolism</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1976</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkDtPwzAYRS3EqxRGNgZPbAm2Y9cuGypPqYIFWC3H_iKM8sJ2KvXfk9BKLPcuR1dXB6FLSnIqOLvpwcVcyFzkki0P0IySpco4k-IQzQgpaMYJEafoLMZvQggXkp2gY6qoZGKGXj99Mo1v8f0tTl-AnY-220DY4q7CPkXcQDJlV_sEEZvWTZAPUwbTw5C8xabva29N8l0bz9FRZeoIF_ueo4_Hh_fVc7Z-e3pZ3a0zy5RMmZOOGgayMNItqSorZivpFHOWlZSzUlpuhXOWKsZAqMJVBtxiIcfzSoESxRxd73b70P0MEJNuxuNQ16aFbohaFZwXXNERzHagDV2MASrdB9-YsNWU6EmfnvRpIbXQo76Rv9oPD2UD7p_-81X8ApimbLI</recordid><startdate>197605</startdate><enddate>197605</enddate><creator>Beale, M G</creator><creator>Chan, J C</creator><creator>Oldham, S B</creator><creator>Deluca, H F</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197605</creationdate><title>Vitamin D: the discovery of its metabolites and their therapeutic applications</title><author>Beale, M G ; Chan, J C ; Oldham, S B ; Deluca, H F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c287t-d7d1a2e73a7d918bf2cf7d82dc2b142b7c4c5ddc1822e583dfaed66745788e853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1976</creationdate><topic>Animals</topic><topic>Calcium - metabolism</topic><topic>Chemical Phenomena</topic><topic>Chemistry</topic><topic>Chronic Kidney Disease-Mineral and Bone Disorder - drug therapy</topic><topic>Chronic Kidney Disease-Mineral and Bone Disorder - metabolism</topic><topic>Dihydroxycholecalciferols - metabolism</topic><topic>Epilepsy - drug therapy</topic><topic>Humans</topic><topic>Hydroxycholecalciferols - metabolism</topic><topic>Hypoparathyroidism - metabolism</topic><topic>Hypophosphatemia, Familial - metabolism</topic><topic>Parathyroid Hormone - metabolism</topic><topic>Phosphorus - metabolism</topic><topic>Pseudohypoparathyroidism - metabolism</topic><topic>Rickets - metabolism</topic><topic>Space life sciences</topic><topic>Structure-Activity Relationship</topic><topic>Uremia - drug therapy</topic><topic>Vitamin D - metabolism</topic><topic>Vitamin D - therapeutic use</topic><topic>Vitamin D Deficiency - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beale, M G</creatorcontrib><creatorcontrib>Chan, J C</creatorcontrib><creatorcontrib>Oldham, S B</creatorcontrib><creatorcontrib>Deluca, H F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beale, M G</au><au>Chan, J C</au><au>Oldham, S B</au><au>Deluca, H F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin D: the discovery of its metabolites and their therapeutic applications</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>1976-05</date><risdate>1976</risdate><volume>57</volume><issue>5</issue><spage>729</spage><epage>741</epage><pages>729-741</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><abstract>Our understanding of the role of vitamin D in calcium-phosphorus metabolism has changed considerably in the last decade. Studies performed in tissue culture, animal, and man have firmly established that the natural compound requires hydroxylation in the liver at the C-25 position and in the kidney at the C-1 position to form the biologically active derivative 1,25-(OH)2D3. These hydroxylation reactions are finely regulated to maintain normal calcium-phosphorus homeostasis: We now regard 1,25-(OH)2D3 as a hormone which is released by the kidney during periods of hypocalcemia. This hormone acts on the intestinal mucosa to facilitate calcium absorption and on bone to increase calcium mobilization. Its function in other tissues is still being evaluated. The active metabolites of vitamin D and several closely related analogs have been synthesized. It has been clearly demonstrated that 1,25-(OH)2D3 and 1alpha-OH-D3 promote healing in uremic bone disease. Administration of small amounts of these compounds has corrected the biochemical disturbances in vitamin D-dependency and hypoparathyroidism. Limited clinical experience with 25-OH-D3 and 1,25-(OH)2D3 in children with familial hypophosphatemia has failed to show convincing evidence of a therapeutic effect. Further clinical studies are needed to fully evaluate the therapeutic potential of this new family of compounds.</abstract><cop>United States</cop><pmid>181725</pmid><doi>10.1542/peds.57.5.729</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-4005
ispartof Pediatrics (Evanston), 1976-05, Vol.57 (5), p.729-741
issn 0031-4005
1098-4275
language eng
recordid cdi_proquest_miscellaneous_83443481
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Animals
Calcium - metabolism
Chemical Phenomena
Chemistry
Chronic Kidney Disease-Mineral and Bone Disorder - drug therapy
Chronic Kidney Disease-Mineral and Bone Disorder - metabolism
Dihydroxycholecalciferols - metabolism
Epilepsy - drug therapy
Humans
Hydroxycholecalciferols - metabolism
Hypoparathyroidism - metabolism
Hypophosphatemia, Familial - metabolism
Parathyroid Hormone - metabolism
Phosphorus - metabolism
Pseudohypoparathyroidism - metabolism
Rickets - metabolism
Space life sciences
Structure-Activity Relationship
Uremia - drug therapy
Vitamin D - metabolism
Vitamin D - therapeutic use
Vitamin D Deficiency - metabolism
title Vitamin D: the discovery of its metabolites and their therapeutic applications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T10%3A35%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20D:%20the%20discovery%20of%20its%20metabolites%20and%20their%20therapeutic%20applications&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Beale,%20M%20G&rft.date=1976-05&rft.volume=57&rft.issue=5&rft.spage=729&rft.epage=741&rft.pages=729-741&rft.issn=0031-4005&rft.eissn=1098-4275&rft_id=info:doi/10.1542/peds.57.5.729&rft_dat=%3Cproquest_cross%3E83443481%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=83443481&rft_id=info:pmid/181725&rfr_iscdi=true